Skip to main navigation Skip to search Skip to main content

Repurposing Screens of FDA-Approved Drugs Identify 29 Inhibitors of SARS-CoV-2

  • Keun Bon Ku
  • , Hye Jin Shin
  • , Hae Soo Kim
  • , Bum Tae Kim
  • , Seong Jun Kim
  • , Chonsaeng Kim
  • Korea Research Institute of Chemical Technology

Research output: Contribution to journalArticlepeer-review

21 Scopus citations

Abstract

COVID-19, caused by the novel coronavirus SARS-CoV-2, has spread globally and caused serious social and economic problems. The WHO has declared this outbreak a pandemic. Currently, there are no approved vaccines or antiviral drugs that prevent SARS-CoV-2 infection. Drugs already approved for clinical use would be ideal candidates for rapid development as COVID-19 treatments. In this work, we screened 1,473 FDA-approved drugs to identify inhibitors of SARS-CoV-2 infection using cell-based assays. The antiviral activity of each compound was measured based on the immunofluorescent staining of infected cells using anti-dsRNA antibody. Twenty-nine drugs among those tested showed antiviral activity against SARS-CoV-2. We report this new list of inhibitors to quickly provide basic information for consideration in developing potential therapies.

Original languageEnglish
Pages (from-to)1843-1853
Number of pages11
JournalJournal of Microbiology and Biotechnology
Volume30
Issue number12
DOIs
StatePublished - 2020

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • COVID-19
  • FDA-approved drugs
  • Repurposing screens
  • SARS-CoV-2

Fingerprint

Dive into the research topics of 'Repurposing Screens of FDA-Approved Drugs Identify 29 Inhibitors of SARS-CoV-2'. Together they form a unique fingerprint.

Cite this